Bridgewater Advisors’s AstraZeneca AZN Stock Holding History

Bridgewater Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$702K	Sell	4,442 -173	-4%	-$32.5K	0.04%	212
2026 Q1	$866K	Sell	4,615 -870	-16%	-$168K	0.05%	157
2025 Q4	$993K	Buy	5,485 +175	+3%	+$30.7K	0.06%	138
2025 Q3	$890K	Buy	5,310 +80	+2%	+$12.1K	0.06%	146
2025 Q2	$774K	Buy	5,230 +147	+3%	+$20.6K	0.06%	169
2025 Q1	$729K	Buy	+5,083	New	+$735K	0.06%	160
2024 Q4	–	Sell	-5,167	Closed	-$777K	–	130
2024 Q3	$777K	Buy	5,167 +10	+0.2%	+$1.61K	0.08%	102
2024 Q2	$810K	Buy	+5,157	New	+$776K	0.1%	94

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bridgewater Advisors's AZN Position: Q2 2026 in Review

Bridgewater Advisors reduced its AstraZeneca (AZN) stake by 3.7% in Q2 2026, selling an estimated $32.5K and leaving 4,442 shares worth $702K. The position accounts for 0.04% of the portfolio, ranked #212.

Bridgewater Advisors first reported a position in AZN in Q2 2024 and has held it in 8 quarters since. The position peaked at $993K in Q4 2025. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Bridgewater Advisors held 4,442 shares of AstraZeneca worth $702K as of Q2 2026.
Bridgewater Advisors sold 173 AstraZeneca shares in Q2 2026, an estimated $32.5K.
AstraZeneca made up 0.04% of Bridgewater Advisors's portfolio in Q2 2026, its #212 holding.
Bridgewater Advisors first reported a position in AstraZeneca in Q2 2024 and has held it in 8 quarters since.
Bridgewater Advisors's AstraZeneca position peaked at $993K in Q4 2025.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Bridgewater Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.